Class of Stock [Axis] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Series A Preferred Stock [Member] Series C-1 Preferred Stock [Member] Series C-2 Preferred Stock [Member] Series D-1 Preferred Stock [Member] Series D-2 Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Asset Purchase Agreement [Member] Business Acquisition [Axis] Avant [Member] Legal Entity [Axis] OncBio Mune Sub Inc [Member] Title of Individual [Axis] Various Investors [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Customer One [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Accounts Receivable [Member] Deferred Revenue [Member] Antidilutive Securities [Axis] Warrant [Member] Stock Options [Member] Convertible Debt Securities [Member] Amarantus BioScience Holdings, Inc. [Member] Long-Lived Tangible Asset [Axis] Laboratory Equipment [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Computer Equipment [Member] Investors [Member] Debt Instrument [Axis] Convertible Note [Member] Securities Purchase Agreement [Member] Scenario [Axis] First Tranche [Member] Second Tranche [Member] Third Tranche [Member] Investor [Member] Note One [Member] Warrant One [Member] Note Two [Member] Warrant Two [Member] Note Three [Member] Warrant Three [Member] First Investors [Member] First Investors [Member] Note [Member] Award Type [Axis] Matthew Schwartz [Member] Securities Purchase Agreement June 2022 [Member] Related Party [Axis] Jeffrey Busch [Member] Demand Promissory Note Agreement [Member] Second Demand Promissory Note Agreement [Member] Demand Promissory Note Agreement One [Member] Securities Purchase Agreement Second November Two Thousand Twenty One [Member] Third Investor [Member] Second investor [Member] Second and Third Investor [Member] Fourth Investor [Member] Fifth Investor [Member] Sixth Investor [Member] Seven Investor [Member] Promissory Note Agreement [Member] Related Party Transaction [Axis] Parties [Member] Note Agreement [Member] First Lessor [Member] Financing Agreement [Member] Second Lessor [Member] Third Lessor [Member] Fourth Lessor [Member] Fifth Lessor [Member] Lease Agreement [Member] First Year [Member] Second year [Member] Third Year [Member] Fourth Year [Member] Fifth Year [Member] Cumulative Effect, Period of Adoption [Axis] Accounting Standards Update 2016-02 Cumulative Effect, Period of Adoption [Member] Lease Amendment [Member] Mr. Kucharchuk [Member] Board of Directors Chairman [Member] May 2021 Securities Purchase Agreement [Member] First November 2021 Securities Purchase Agreement [Member] First April 2022 Securities Purchase Agreement [Member] Four Convertible Notes [Member] May 2022 Securities Purchase Agreement [Member] June 2022 Securities Purchase Agreement [Member] Danica Holley [Member] Majority Shareholder [Member] Board of Directors [Member] Two Consultants [Member] Subscription Agreement [Member] Plan Name [Axis] 2011 Stock Option Plan [Member] Derivative Instrument [Axis] Equity Option [Member] 2022 Equity Incentive Plan [Member] Financial Instrument [Axis] First November 2021 [Member] Second November 2021 [Member] Third November 2021 [Member] First January 2022 [Member] Second January 2022 [Member] First April 2022 [Member] Second April 2022 [Member] May 2022 [Member] June 2022 [Member] July 2022 [Member] Dr. Michael Ruxin [Member] Ruxin Employment Agreement [Member] 2022 Equity Incentive Plan [Member] Share-Based Payment Arrangement, Option [Member] Busch Employment Agreement [Member]. Restricted Stock Units (RSUs) [Member] 2020 Equity Incentive Plan [Member] Thomas E Chilcott, III [Member] Offer Letter [Member] Consultant [Member] Scientific Advisory Board Service Agreement [Member] Pathology Advisory Board Service Agreement [Member] Consulting Agreement [Member] Exclusive License Agreement [Member] George Mason University [Member] Sublicense Royalty [Member] License Agreement [Member] National Institutes of Health [Member] Lease Agreements [Member] Two Notes Payable [Member] Acts Effective Date [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Gunnar [Member] Debenture [Member] Chief Financial Officer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS: Cash Accounts receivable, net Other receivable (related party $0 in 2022 and $21,711 in 2021) Prepaid expenses and other current assets Marketable securities Laboratory supplies Total Current Assets OTHER ASSETS: Property and equipment, net Finance right-of-use assets, net Operating right-of-use asset, net Deferred offering costs Security deposits Total Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT CURRENT LIABILITIES: Accounts payable Accounts payable - related parties Accrued liabilities Accrued liabilities - related parties Accrued compensation Accrued director compensation Contract liabilities Convertible notes - related parties, net of discount Notes payable - related parties Notes payable - current Financing lease liability - current Operating lease liability - current Insurance payable Subscriptions payable Contingent liabilities Total Current Liabilities LONG-TERM LIABILITIES: Financing lease liability Operating lease liability Convertible notes - related parties net of discount, net of current portion Convertible notes, net of discount Total Liabilities Commitments and Contingencies (Note 11) Temporary equity value STOCKHOLDERS’ DEFICIT: Preferred stock value Common stock: $0.0001 par value, 100,000,000,000 shares authorized; 6,151,499,919 and 5,124,164,690 issued and outstanding at September 30, 2022 and 2021, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit Total Liabilities and Stockholders’ Deficit Other receivable related party Temporary equity, par or stated value per share Temporary equity, shares authorized Temporary equity, shares issued Temporary equity, shares outstanding Temporary equity, liquidation preference Preferred stock, par or stated value per share Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par or stated value per share Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding REVENUES, NET COST OF REVENUE GROSS PROFIT OPERATING EXPENSES: Professional fees Compensation expense Licensing fees General and administrative expenses Total Operating Expenses LOSS FROM OPERATIONS OTHER INCOME (EXPENSE): Interest expense, net Gain on debt extinguishment, net Unrealized loss on marketable securities Unrealized loss on exchange rate Gain on disposal of subsidiary Gain on dissolution of subsidiary Total Other Income (Loss), net NET LOSS Preferred stock dividend and deemed dividend NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS NET LOSS PER COMMON SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS: Basic and Diluted WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted Beginning balance, value Beginning balance, shares Adjustment related to Series A preferred prior period redemption payment Beneficial conversion feature related to a convertible note - related party recorded as debt discount Relative fair value of warrant issued in connection with convertible notes - related party recorded as debt discount Series E preferred stock dividend Series F preferred stock dividend Beneficial conversion feature related to issuance of Series F preferred stock Relative fair value of warrant issued in connection with the sale Series F preferred stock Net loss Relative fair value of warrant issued in connection with convertible notes recorded as debt discount Issuance of common stock in connection with conversion of Series C-1 preferred stock Issuance of common stock in connection with conversion of series C-1 preferred stock, shares Issuance of common stock in connection with conversion of Series C-2 preferred stock Issuance of common stock in connection with conversion of series C-2 preferred stock, shares Issuance of common stock in connection with settlement of accounts payable Issuance of common stock in connection with settlement of accounts payable, shares Issuance of common stock in connection with subscriptions payable Issuance of common stock in connection with subscriptions payable, shares Relative fair value of additional warrants issued in connection with modification of convertible notes - related party recorded as debt discount Relative fair value of additional warrants issued in connection with modification of convertible notes recorded as debt discount Accretion of stock-option expense Correction for rounding error Correction for rounding error, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation on property and equipment and finance ROU assets Non-cash lease cost Accretion of stock option expense Amortization of debt discount Bad debt Gain on debt extinguishment Unrealized loss on exchange rate Unrealized loss on marketable securities Gain on dissolution of subsidiary Gain on disposal of subsidiary Gain on modification of operating lease Change in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Laboratory supplies Accounts payable Accrued liabilities and other liabilities Contract liabilities NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Adjustment related to Series A preferred prior period redemption payment Proceeds from disposal of a subsidiary Purchase of property and equipment NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of preferred stock Proceeds from sale of common stock Proceeds from convertible debt - related party Proceeds from convertible debt Proceeds of notes payable - related party Repayment of notes payable - related party Repayment of financed lease Deferred offering costs Payments for preferred stock dividends NET CASH PROVIDED BY FINANCING ACTIVITIES NET CHANGE IN CASH CASH, beginning of the year CASH, end of the year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid during the period for: Interest Income taxes Non-cash investing and financing activities: Series E preferred stock dividend Series F preferred stock dividend Initial amount of operating ROU asset and related liability Relative fair value of warrant issued in connection with convertible notes - related party recorded as debt discount Relative fair value of warrant issued in connection with convertible notes recorded as debt discount Relative fair value of additional warrants issued in connection with modification of convertible notes - related party recorded as debt discount Relative fair value of additional warrants issued in connection with modification of convertible notes recorded as debt discount Beneficial conversion feature related to a convertible note - related party recorded as debt discount Beneficial conversion feature related to issuance of Series F preferred stock Relative fair value of warrant issued in connection with the sale Series F preferred stock Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Combination and Asset Acquisition [Abstract] DISPOSAL OF SUBSIDIARIES Investments, Debt and Equity Securities [Abstract] MARKETABLE SECURITIES Receivables [Abstract] ACCOUNTS RECEIVABLE Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Debt Disclosure [Abstract] DEBT Lease Liabilities LEASE LIABILITIES Related Party Transactions [Abstract] RELATED-PARTY TRANSACTIONS Equity [Abstract] STOCKHOLDERS’ DEFICIT Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Going Concern Use of Estimates Fair Value of Financial Instruments and Fair Value Measurements Cash and Cash Equivalents Prepaid Assets Laboratory Supplies Property and Equipment Impairment of Long-Lived Assets Stock-Based Compensation Revenue Recognition and Contract Assets and Liabilities Contract Liabilities Cost of Revenue Accounts Receivable and Allowance for Doubtful Accounts Research and Development Concentrations Basic and Diluted Loss Per Share Income Taxes Related Parties Leases Recent Accounting Pronouncements SCHEDULE OF CONTRACT LIABILITIES SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING SCHEDULE OF ACCOUNTS RECEIVABLE SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF CONVERTIBLE NOTES PAYABLE SCHEDULE OF FINANCIAL LEASE RIGHT-OF-USE ASSETS SCHEDULE OF FINANCING LEASE LIABILITY RELATED TO FINANCING RIGHT-OF-USE ASSETS SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER FINANCING LEASE SCHEDULE OF OPERATING RIGHT-OF-USE ASSET SCHEDULE OF OPERATING LEASE LIABILITY RELATED TO RIGHT-OF-USE ASSETS SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS OF OPERATING LEASE SCHEDULE OF RELATED PARTIES TRANSACTION SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF WARRANTS SCHEDULE OF EFFECTIVE INCOME TAX RATE SCHEDULE OF DEFERRED TAX ASSETS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares issued Percentage of voting Interests acquired Common stock shares authorized Conversion of stock shares converted Sale of stock percentage of ownership after transaction Gross proceeds from issuance of stock Contract liabilities beginning balance Billings and cash receipts on uncompleted contracts Less: revenues recognized during the period Total contract liabilities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total antidilutive securities excluded from computation of earnings Schedule of Product Information [Table] Product Information [Line Items] Net loss Net cash used in operations Accumulated deficit Stockholders' deficit Working capital deficit Property and equipment, estimated useful lives Contract liabilities, revenue recognized Uncompleted contract liabilities, revenue recognized Research and development transaction term Research and development expense Cash FDIC insured amount Revenue Concentration risk, percentage Accounts receivable Deferred revenue Patient reporting and contract research expense Uncertain tax positions Income tax, interest and penalties Gain loss on dissolution of subsidiary Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Stock Issued During Period, Shares, Acquisitions Stock Issued During Period, Value, Acquisitions Marketable Securities, Unrealized Gain (Loss) Marketable Securities Accounts receivable Less: allowance for doubtful accounts Bad debts Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Laboratory equipment Estimated useful life in years Furniture Leasehold improvements Computer equipment Property and equipment gross Less accumulated depreciation Property and equipment, net Depreciation and amortization expense Principal amount Less: debt discount Convertible notes payable, net Principal amount – related parties Less: debt discount – related parties Convertible notes payable - related parties, net Less: current portion Convertible notes payable - related parties, net – long-term Total convertible notes payable, net Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Warrants purchase Principal balance Annual interest rate Interest rate increase decrease Maturity date Proceeds from related party debt Conversion price Interest rate Accrued interest Principal balance Accrued interest Convertible long term notes payable Net of discount Exercise price of warrants Fair value Debt Instrument, Convertible, Beneficial Conversion Feature Aggregate investment amount Warrants and rights outstanding Debt instrument description Proceeds from issuance of debt Interest rate Warrants to purchase price Fair value Interest rate Debt conversion description Principal balance Parties increased the principal amount Accrued interest Schedule Of Financial Lease Right-of-use Assets Financing ROU assets Less accumulated depreciation Balance of Financing ROU assets Schedule Of Financing Lease Liability Related To Financing Right-of-use Assets Financing lease payables for equipment Total financing lease payables Payments of financing lease liabilities Total Less: short term portion Long term portion 2023 2024 2025 Total minimum financing lease payments Less: discount to fair value Total financing lease payable on September 30, 2022 Operating office lease Less accumulated reduction Balance of Operating ROU asset Operating office lease Total operating lease liability Reduction of operating lease liability Total Less: short term portion Long term portion 2023 2024 2025 2026 2027 and thereafter Total minimum non-cancellable operating lease payments Less: discount to fair value Total operating lease liability on September 30, 2022 Monthly base rent Lessee operating lease term Lease desription Financing lease payable Finance lease, discount rate Depreciation expense financing ROU asset Operating discount rates Rentable square feet Monthly rent, description Operating asset Operating lease, liability Gain on lease modification Lease, Cost Base lease cost Lease other expense Convertible notes principal – related parties Discount on convertible notes - related parties Note payable principal – related parties Accrued liabilities - related parties Accounts payable – related parties Other receivable - related party Total Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Consulting fees Expense reimbursements Interest rate Warrants purchase Debt description Warrants to purchase Fair value Aggregate proceeds Aggregate investment amount Advanced to related party Bad debt expense Related party receivable Number of Shares Subject to Issuance, Outstanding Weighted-average Exercise Price, Outstanding Outstanding-Aggregate Intrinsic Value, Beginning Number of Shares Subject to Issuance, Granted Weighted-average Exercise Price, Granted Number of Shares Subject to Issuance, Outstanding Weighted-average Exercise Price, Outstanding Weighted-average Remaining Contractual Term, Outstanding Ending Outstanding-Aggregate Intrinsic Value, Ending Number of Shares Subject to Issuance, Exercisable Weighted-average Exercise Price, Exercisable Weighted-average Remaining Contractual Term Exercisable-Aggregate Intrinsic Value Number of shares, non vested and expected to vest, beginning balance Weighted-average Exercise Price, Outstanding Weighted-average Exercise Price, Granted Number of Shares Subject to Vested Weighted-average Exercise Price, Vested Number of shares, non vested and expected to vest, ending balance Weighted-average Exercise Price, Outstanding Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Warrants, Outstanding Beginning balance Weighted Average Exercise Price, Outstanding Beginning balance Weighted Average Remaining Contractual Term (Years), Beginning Balance Outstanding Aggregate Intrinsic Value, Beginning Balance Outstanding Number of Warrants, Issued in connection with a convertible debt - related party (see Note 6 and Note 8) Weighted Average Exercise Price, Issued in connection with a convertible debt - related party (see Note 6 and Note 8) Weighted Average Remaining Contractual Term (Years), Issued in connection with a convertible debt - related party (see Note 6 and Note 8) Number of Warrants, Issued in connection with a Series F preferred stock - related party Weighted Average Exercise Price, Convertible debt Number of Warrants, Issued in connection with a Convertible debt Weighted Average Remaining Contractual Term (Years), Convertible debt Number of Warrants, Outstanding Ending balance Weighted Average Exercise Price, Outstanding Ending balance Weighted Average Remaining Contractual Term (Years), Ending Balance Outstanding Aggregate Intrinsic Value, Ending Balance Outstanding Number of Warrants, Exercisable Weighted Average Exercise Price, Exercisable Weighted Average Remaining Contractual Term (Years), Exercisable Aggregate Intrinsic Value, Exercisable Schedule of Stock by Class [Table] Class of Stock [Line Items] Common stock, par value Preferred stock designated Stockholder voting rights Preferred stock, par value Preferred stock, stated value Conversion price Conversion percentage Common stock outstanding, percentage Common stock issued upon conversion Debt interest rate Preferred stock, conversion basis Public offering, description Aggregate investment amount Beneficial conversion feature amount Sereis E preferred stock dividend Dividends payable Sale of stock number of shares issued in transaction Proceeds from Convertible Debt Unamortized discount Common stock issued for conversion Common stock issued upon conversion Issuance of common stock in connection with settlement of accounts payable Issuance of common stock in connection with settlement of accounts payable shares Share price Purchase price Sale of stock price per share Number of share authorized Stock options granted Common stock capital shares reserved for future issuance Fair market value, percentage Exercise price Expected dividend yield Expected volatility Risk-free interest rate Expected life (in years) Stock based compensation expense Stock option expense Options vested and exercisable Unvested stock based compensation expense Aggregate intrinsic value Exercise price Warrants outstanding Warrants exercisable Warrants valued Shares issued Warrants issued Loss Contingencies [Table] Loss Contingencies [Line Items] Annual base salary Annual decretionary bonus percentage Restricted stock, shares Stock options aggregate Stock options exercise price Annual base salary Accrued director compensation Deferred compensation arrangements overall description Compensation fees Payments for fees Accrued consulting fees Royalty expense Revenue percentage Advance royalties Non refundable minimum annual royalty Lessee operating lease description Lease period Consideration liability Outstanding principal balance Accrued interest payable Loss contingency damages sought value Litigation settlement number of shares Litigation settlement shares, value Income tax benefit at U.S. statutory rate of 21%  Income tax benefit – state Non-deductible expenses Change in valuation allowance Total provision for income tax Percentage of statutory rate Net operating loss carry-forwards Total deferred tax asset Less: valuation allowance Net deferred tax asset Operating loss carryforward Valuation allowance Net operating loss carryforward Tax credit Tax year descriptions Subsequent Event [Table] Subsequent Event [Line Items] Principal balance Warrant received Warrant coverage percentage Proceeds from intial public offerings Commission payable Offering expenses Offering costs Agreement description Legal fees payable Advisory fee payable Debt maturity date Proceeds from common stock Warrant reason for issuing, descriptions Warrant exercise price Interest payable Percentage of increase in preferred stock Interest payable Dividends payable Debt conversion amount Outstanding percentage Salaries Base salary percentage Sharebased compensation available for grant Vesting percentage Bonus payable Subscription payable current. Onc Bio Mune Sub Inc [Member] Various Investors [Member] Current portion of ccrued liabilities - related party. Amarantus BioScience Holdings, Inc. [Member] Convertible debt related party noncurrent. Convertible debt related party current. Annual decretionary bonus percentage. Dr. Michael Ruxin [Member] Ruxin Employment Agreement [Member] Laboratory Equipment [Member] Laboratory equipment. Jeffrey Busch [Member] Busch Employment Agreement [Member]. Debt instrument face amount related party. Debt instrument unamortized discount related party. Series C-2 Preferred Stock [Member] Series D 1 Preferred Stock [Member] Offer Letter [Member] Series D-2 Preferred Stock [Member] Thomas e chilcott three [Member] Consultant [Member] Scientific Advisory Board Service Agreement [Member] Investors [Member] Convertible note [Member] Securities purchase agreement [Member] Pathology Advisory Board Service Agreement [Member] Consulting Agreement [Member] Exclusive License Agreement [Member] George Mason University [Member] Revenue percentage. Sublicense Royalty [Member] License Agreement [Member] National Institutes of Health [Member] Non Refundable Minimum Annual Royalty. Lease Agreement [Member] Lease Amendment [Member] Monthly rent, description. Two Notes Payable [Member] Licensing fees. Consulting fees. Mr. Kucharchuk [Member] First tranche [Member] Second Tranche [Member] Third Tranche [Member] Promissory Note Agreement [Member] Accrued interest paid. Net operating loss carryforward. Acts Effective Date [Member] Note One [Member] Warrant one [Member] Note Two [Member] Warrant two [Member] Note Three [Member] Warrant Three [Member] Demand Promissory Note Agreement [Member] First Investors [Member] First Investors [Member] Note [Member] First November 2021 [Member] Relative fair value of warrant issued in connection with convertible notes recorded as debt discount. Issuance of common stock in connection with settlement of accounts payable. Matthew Schwartz [Member] Issuance of common stock in connection with subscription payable. Issuance of common stock in connection with settlement of accounts payable, shares. Issuance of common stock in connection with subscription payable, shares. Relative fair value of additional warrants issued in connection with modification of convertible notes related party recorded as debt discount. Percentage of warrants to purchase shares. Relative fair value of additional warrants issued in connection with modification of convertible notes recorded as debt discount. Correction for rounding error. Correction for rounding error, shares. Securities Purchase Agreement June 2022 [Member] Gunnar [Member] Non cash lease cost. Gains losses on modification of operating lease. Adjustment related to Series A preferred prior period redemption payment. Proceeds from convertible debt related party. Cash Paid During Period For Interest [Abstract] Preferred stock dividend one. Preferred stock dividend two. Initial Amount Of Operating Rou Asset And Related Liability. Relative fair value of warrants issued in connection with convertible notes related party recorded as debt discount. Relative fair value of additional warrants issued in connection with modification of convertible notes related party recorded as debt discount. Second Demand Promissory Note Agreement [Member] Proceed from disposal of a subsidiary. Relative fair value of warrants issued in connection with convertible notes recorded as debt discount. Relative fair value of additional warrants issued in connection with modification of convertible notes recorded as debt discount. Beneficial conversion feature related to a convertible note - related party recorded as debt discount. Relative fair value of warrant issued in connection with the sale Series F preferred stock. Relative Fair Value Of Warrant Issued In Connection With Sale Series F Preferred Stock. Asset Purchase Agreement [Member] Percentage of voting interest acquired. Avant [Member] Bonus payable. Working capital deficit. Securities Purchase Agreement Second November Two Thousand Twenty One [Member] Prepaid Asset [PolicyText Block] Third Investor [Member] Laboratory Supplies [Policy Text Block] Second investor [Member] Billings and cash receipts on uncompleted contracts. Revenues recognized during the period. Second and Third Investor [Member] Uncompleted Contract With Customer Liability Revenue Recognized. Related Parties [Policy Text Block] Stock Options [Member] Customer One [Member] Deferred Revenue [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Fourth Investor [Member] Convertible Note Principal Related Party. Accrued liabilities related parties. Fifth Investor [Member] Sixth Investor [Member] Seven Investor [Member] Note Agreement [Member] Board of Directors [Member] First Lessor [Member] Financing Agreement [Member] Second Lessor [Member] Third Lessor [Member] Fourth Lessor [Member] Fifth Lessor [Member] Schedule Of Financing Right of use Assets [Table Text Block] Depreciation expense financing ROU asset. Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. Financing lease payables for equipment. Financing lease payables. Payments of financing lease liabilities. First Year [Member] Second year [Member] Third Year [Member] Fourth Year [Member] Fifth Year [Member] Series C-1 Preferred Stock [Member] Operating office lease. Base lease cost. Lease other expense. Less accumulated reduction. Operating Office Lease Liability. Total lease liabilities. Reduction of operating lease liability. After year four. Demand Promissory Note Agreement One [Member] Public offering description. Beneficial conversion feature amount. Two Consultants [Member] Subscription Agreement [Member] 2011 Stock Option Plan [Member] Second November 2021 [Member] Third November 2021 [Member] First January 2022 [Member] Second January 2022 [Member] First April 2022 [Member] Second April 2022 [Member] May 2022 [Member] June 2022 [Member] July 2022 [Member] Warrants issued Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Issued In Connection With Issued In Connection With A Convertible Debt Related Party. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Issued In Connection With Issued In Connection With A Series F Preferred Stock. Share based compensation arrangement by share based payment award non-option equity instruments warrants issued in connection with issued in connection with convertible debt. The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan. Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued In Connection With Convertible Debt Related Party Expired In Period Weighted Average Granted. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Sale And Recapitalization Transaction Expired In Period Weighted Average Granted. The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of non-option equity outstanding and currently exercisable under the non-option equity plan. Share Based Compensation Arrangement Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning. Share Based Compensation Arrangement By Share Based Payment Convertible Debt Related Party Weighted Average Remaining Contractual Term Debt. Share Based Compensation Arrangement By Share Based Payment Warrants Issued In Connection Weighted Average Remaining Contractual Term Debt1. Weighted average remaining contractual term for non-option equity awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Sharebased compensation arrangement by sharebased payment award non options exercisable intrinsic value. Convertible debt related party. Dividends preferred stock, stock. Beneficial conversion feature related to issuance of Series F preferred stock. Relative fair value of warrant issued in connection with the sale Series F preferred stock. Issuance of common stock in connection with conversion of series C-2 preferred stock. Issuance of common stock in connection with conversion of series C-2 preferred stock, shares Adjustment related to Series A preferred prior period redemption payment. Schedule Of Financing Lease Liability Related To Financing Right-Of-Use Assets [Table Text Block] Schedule Of Operating Right-Of-Use Asset [Table Text Block] Schedule Of Operating Lease Liability Related To Right-Of-Use Assets [Table Text Block] May 2021 Securities Purchase Agreement [Member] First November 2021 Securities Purchase Agreement [Member] First April 2022 Securities Purchase Agreement [Member] Four Convertible Notes [Member] May 2022 Securities Purchase Agreement [Member] June 2022 Securities Purchase Agreement [Member] Contract Liabilities [Policy Text Block] Parties [Member] Danica Holley [Member] Warrant coverage percentage. 2022 Equity Incentive Plan [Member] Share based payment award non options outstanding intrinsic value balance. 2020 Equity Incentive Plan [Member] 2022 Equity Incentive Plan [Member] Agreement description. Debenture [Member] Outstanding percentage. Base salary percentage. First Investors [Member] [Default Label] 2022 Equity Incentive Plan [Member] [Default Label] Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Foreign Currency Transaction Loss, before Tax Nonoperating Income (Expense) Dividends, Preferred Stock Weighted Average Number of Shares Outstanding, Basic Shares, Outstanding Foreign Currency Transaction Gain (Loss), Unrealized Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Materials and Supplies Increase (Decrease) in Accounts Payable Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities AdjustmentRelatedToPreferredSharesPriorPeriodRedemptionPayment Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Related Party Debt Payment of Financing and Stock Issuance Costs Payments of Ordinary Dividends, Preferred Stock and Preference Stock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations PreferredStockDividendTwo RelativeFairValueOfWarrantsIssuedInConnectionWithConvertibleNotesRelatedPartyRecordedAsDebtDiscount RelativeFairValueOfWarrantsIssuedInConnectionWithConvertibleNotesRecordedAsDebtDiscount RelativeFairValueOfAdditionalWarrantIssuedInConnectionWithModificationOfConvertibleNotesRelatedPartyRecordedAsDebtDiscount RelativeFairValueOfAdditionalWarrantIssuedInConnectionWithModificationOfConvertibleNotesRecordedAsDebtDiscount BeneficialConversionFeatureRelatedToConvertibleNoteRelatedPartyRecordedAsDebtDiscount BeneficialConversionFeatureRelatedToIssuanceOfSeriesFPreferredStock RelativeFairValueOfWarrantIssuedInConnectionWithSaleSeriesFPreferredStock Accounts Receivable, Allowance for Credit Loss, Current Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment DebtInstrumentUnamortizedDiscountRelatedParty Convertible Debt Debt Instrument, Interest Rate, Increase (Decrease) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Debt Instrument, Interest Rate, Effective Percentage Debt Conversion, Converted Instrument, Amount Interest Payable, Current Finance Lease, Right-of-Use Asset, Accumulated Amortization FinancingLeasePayables Finance Lease, Liability, to be Paid Finance Lease, Liability, Undiscounted Excess Amount OperatingOfficeLeaseLiability OperatingLeaseLiabilities Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount AccruedLiabilitiesRelatedParties Due from Other Related Parties, Current Due to Related Parties, Current Investments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValueBalance ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice Preferred Stock, Convertible, Conversion Price Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Accrued Salaries Income Tax Expense (Benefit) Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Debt Instrument, Annual Principal Payment Dividends Payable